Given the fact that the PDGF is the predominant trigger in PASMCs’ proliferation and migration [16], it is not surprising that using receptor tyrosine kinase inhibitors, such as imatinib against the PDGF receptor (PDGFR), has been regarded as an attractive strategy to treat PAH. The gene discussed is NTRK1; the disease is pulmonary arterial hypertension.